Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
HLA CLASS-I
EXPRESSION
0301 basic medicine
Anti-HIV Agents
3207 Medical Microbiology
32 Biomedical and Clinical Sciences
HIV Infections
DETERMINANTS
613
Article
03 medical and health sciences
anzsrc-for: 32 Biomedical and Clinical Sciences
ANTIRETROVIRAL THERAPY
616
2.1 Biological and endogenous factors
Humans
anzsrc-for: 3207 Medical Microbiology
POPULATION
anzsrc-for: 3204 Immunology
Science & Technology
MORTALITY
DISEASE PROGRESSION
3 Good Health and Well Being
Viral Load
INFECTED INDIVIDUALS
CD4 Lymphocyte Count
3. Good health
3204 Immunology
Multidisciplinary Sciences
Infectious Diseases
Withholding Treatment
T-CELLS
HIV-1
HIV/AIDS
Sexually Transmitted Infections
Science & Technology - Other Topics
Infection
Biomarkers
RESPONSES
DOI:
10.1038/ncomms9495
Publication Date:
2015-10-09T11:18:00Z
AUTHORS (22)
ABSTRACT
AbstractTreatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control’ (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (148)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....